Page last updated: 2024-11-04

ethylenediamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ethylenediamine, also known as 1,2-diaminoethane, is a colorless liquid with a pungent ammonia-like odor. It is a strong base and a good chelating agent, meaning it can bind to metal ions. Ethylenediamine is synthesized by reacting ethylene dichloride with ammonia under pressure. It is used in the production of various chemicals, including polymers, resins, pharmaceuticals, and pesticides. Ethylenediamine is also used as a solvent, a corrosion inhibitor, and a fuel additive. It is an important reagent in organic chemistry, where it is used to form complexes with metal ions. Ethylenediamine is studied because of its versatility and its ability to form stable complexes with a variety of metal ions.'

ethylenediamine: RN given refers to parent cpd; edamine is the recommended contraction for the ethylenediamine radical [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ethylenediamine : An alkane-alpha,omega-diamine in which the alkane is ethane. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3301
CHEMBL ID816
CHEBI ID30347
MeSH IDM0098309

Synonyms (134)

Synonym
en
CHEBI:30347 ,
1,2-diamino-ethaan [dutch]
dimethylenediamine
ethylenediamine [jan]
aethaldiamin [german]
ethylendiamine
aminophylline injection
ethylene-diamine [french]
ethylenediamine [un1604] [corrosive]
einecs 203-468-6
ai3-24231
nci-c60402
un1604
epa pesticide chemical code 004205
1,2-ethylenediamine
aethylenediamin [german]
algicode 106l
1,2-diaminoethane
amerstat 274
hsdb 535
ethyleendiamine [dutch]
brn 0605263
ccris 5224
1,2-diamino-ethano [italian]
caswell no. 437
1,2-diaminoaethan [german]
beta-aminoethylamine
bdbm7972
chembl816 ,
ethane,1,2-diamino
inchi=1/c2h8n2/c3-1-2-4/h1-4h
ethane-1,2-diamine
1,2-ethanediamine
NCGC00091527-01
ethylenediamine
107-15-3
ethylenediamine, bioxtra
ethylenediamine, meets usp testing specifications
ethylenediamine, reagentplus(r), >=99%
ethylenediamine (usp/jp17)
D01114
ethylenediamine, purified by redistillation, >=99.5%
ethylene diamine
edamine
AKOS000118850
ethylenediamine anhydrous
E0081
E0077
NCGC00091527-02
ethyl diamine
EDN ,
ethyleendiamine
1,2-diamino-ethaan
ethylenediamine [usp:jan]
aethaldiamin
ethylenediamine [un1604] [corrosive]
1,2-diaminoaethan
4-04-00-01166 (beilstein handbook reference)
edamine [inn]
unii-60v9stc53f
1,2-diamino-ethano
aethylenediamin
60v9stc53f ,
ec 203-468-6
ethylene-diamine
NCGC00258754-01
tox21_201202
dtxcid501881
cas-107-15-3
tox21_111145
dtxsid5021881 ,
BP-20367
EPITOPE ID:117724
STL264241
ethylenediamine [hsdb]
ethylenediamine [ep monograph]
ethylenediamine [mart.]
ethylenediamine [who-dd]
ethylenediamine [usp monograph]
tizanidine hydrochloride impurity h [ep impurity]
ethylenediamine [mi]
ethylenediamine [ii]
ethylenediamine [inci]
1,2-ethylendiamine
ethane-1, 2-diamine
2-aminoethylamine
ethane 1,2-diamine
1,2-diaminoethan
1,2-diamino-ethane
1,2-ethylene-diamine
ethylene di amine
ethylene - diamine
1,4-diazabutane
n,n'-ethylene diamine
n,n'-ethylenediamine
1,2-ethylene diamine
ethylenediarnine
nh2(ch2)2nh2
h2nch2ch2nh2
.beta.-aminoethylamine
un 1604
mfcd00008204
J-001723
ethylenediamine, puriss. p.a., absolute, >=99.5% (gc)
ethylenediamine, saj special grade, >=99.0%
ethylenediamine, analytical standard
quadrapure(r) aea, 100-400 mum particle size, extent of labeling: 1.3 mmol/g loading, 1 % cross-linked with divinylbenzene
ethylenediamine, vetec(tm) reagent grade, >=98%
ethylenediamine, for synthesis, 99.0%
ethylenediamine; ethane-1,2-diamine
ethylenediamine (anhydrous)
333-18-6 (di-hydrochloride)
ethylenediamine, 8ci
5700-49-2 (di-hydriodide)
624-59-9 (di-hydrobromide)
ethylenediamine (usp/jp15)
Q411362
DB14189
STR00309
1,2-diaminoethane phase i beta
1,2-diaminoethane phase i alpha
1,2-diaminoethane phase ii
EN300-19398
ethylenediamine (mart.)
caswell no 437
tizanidine hydrochloride impurity h (ep impurity)
ethylenediamine (ii)
ethylenediamine (usp monograph)
alpha,omega-ethanediamine
ethylenediamine mod
pesticide code 004205
ethylenediamine (ep monograph)
Z104473714

Research Excerpts

Overview

Ethylenediamine is an inhibitor of Na+/K+-ATPase processes. It is an excipient with many industrial and pharmaceutical uses.

ExcerptReferenceRelevance
"(1) Ethylenediamine is an inhibitor of Na+- and K+-activated processes of Na+/K+-ATPase, i.e. "( Ethylenediamine as active site probe for Na+/K+-ATPase.
De Pont, JJ; Leunissen, J; Schuurmans Stekhoven, FM; Swarts, HG; Zou, YS, 1989
)
2.28
"Ethylenediamine is an excipient with many industrial and pharmaceutical uses. "( Ethylenediamine, profile of a sensitizing excipient.
Zuidema, J, 1985
)
3.15

Effects

ExcerptReferenceRelevance
"Ethylenediamine has been used as an agent for softening very hard woods prior to sectioning on a sliding microtome. "( The use of ethylenediamine in softening hard plant structures for paraffin sectioning.
Carlquist, S, 1982
)
2.1

Treatment

ExcerptReferenceRelevance
"Ethylenediamine treatment yielded fewer surface amino groups, and in addition an increase in crystallinity as well as degradation of PHBV was evident from Fourier transform infrared spectroscopy."( Introducing amine functionalities on a poly(3-hydroxybutyrate-co-3-hydroxyvalerate) surface: comparing the use of ammonia plasma treatment and ethylenediamine aminolysis.
Broota, P; Fredericks, P; Grøndahl, L; Keen, I; Rintoul, L; Trau, M, 2006
)
1.26

Toxicity

ExcerptReferenceRelevance
"In accordance with a case report of a 7-year-old boy with bronchial asthma, who was twice treated with aminophylline and each time reacted upon this with an aggressive behaviour, which was completely abolished after stopping the medication and which did not appear after application of theophylline, we became suspicious, that this side effect could be due only to the ethylenediamine."( [Aggressive behavior as a side effect of ethylenediamine (but not of theophylline)].
Niggemann, B, 1985
)
0.7
"We report DNA cleavage by ruthenium(II) arene anticancer complex [(η(6)-p-terp)Ru(II)(en)Cl](+) (p-terp=para-terphenyl, en=1,2-diaminoethane, complex 1) after its photoactivation by UVA and visible light, and the toxic effects of photoactivated 1 in cancer cells."( Photo-induced DNA cleavage and cytotoxicity of a ruthenium(II) arene anticancer complex.
Brabec, V; Kasparkova, J; Pracharova, J; Sadler, PJ; Stepankova, J, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" The rats, which were randomized along with the rest of the animals on the toxicity study, were taken for pharmacokinetic experiments at the specified time."( Age-dependent pharmacokinetic changes of ethylenediamine in Fischer 344 rats parallel to a two-year chronic toxicity study.
McKelvey, JA; Tallant, MJ; Yang, RS, 1984
)
0.53
" There were no significant differences in material balance or pharmacokinetic parameters among animals receiving DETA."( Pharmacokinetics and material balance studies of diethylenetriamine trihydrochloride in the Fischer 344 rat following oral, endotracheal or intravenous dosing.
Leung, HW; Tyler, TR,
)
0.13
" The following results were obtained: 1) Pharmacokinetic parameters of plasma theophylline after an intravenous bolus injection were close to those after the dosing of aminophylline in dogs by a crossover method."( Pharmacokinetic study of theophylline in dogs after intravenous administration with and without ethylenediamine.
Kawai, H; Kojima, J; Kokubun, S; Matsumoto, T; Onodera, K, 2000
)
0.53

Compound-Compound Interactions

ExcerptReferenceRelevance
"5% LiCl, combined with intrinsic viscosity measurements in Cuen."( A re-investigation of the Mark-Houwink-Sakurada parameters for cellulose in Cuen: a study based on size-exclusion chromatography combined with multi-angle light scattering and viscometry.
Christensen, BE; Kes, M, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" There were no apparent age-, sex-, and/or chronic dosing-related differences in absorption rate constant and terminal half-life."( Age-dependent pharmacokinetic changes of ethylenediamine in Fischer 344 rats parallel to a two-year chronic toxicity study.
McKelvey, JA; Tallant, MJ; Yang, RS, 1984
)
0.53
" Over much of the loading range, the CO(2) absorption rate with 12 M EDA is comparable to 7 M MEA."( Aqueous ethylenediamine for CO(2) capture.
Chen, X; Nguyen, T; Rochelle, GT; Voice, AK; Zhou, S, 2010
)
0.79
"Cationic β-lactoglobulin (CBLG) was developed as a bioavailability enhancer for poorly absorbed bioactives."( Cationic β-lactoglobulin nanoparticles as a bioavailability enhancer: protein characterization and particle formation.
Li, Y; Luo, Y; Teng, Z; Wang, Q; Zhang, B, 2013
)
0.39
" The changes of metals speciation showed the reduction of metals bioavailability during anaerobic digestion, which might weaken the stimulative effects of trace metals."( Enhanced anaerobic digestion of food waste by trace metal elements supplementation and reduced metals dosage by green chelating agent [S, S]-EDDS via improving metals bioavailability.
Li, A; Zhang, L; Zhang, W, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Ethylenediamine dihydrochloride (EDA X 2 HCl) was incorporated in the diet of Fischer 344 rats at dosage goals of 0.

ExcerptRelevanceReference
" The serum iodine concentration was correlated with the dosage of EDDI."( Serum distribution of iodine after oral administration of ethylenediamine dihydriodide in cattle.
Berg, JN; Maas, J; Petersen, RG, 1989
)
0.52
" For each rat dosed, three types of studies were conducted: (1) plasma kinetics, (2) material balance, and (3) histological evaluation, including autoradiography of the skin sample from the dosing area."( Biochemical and morphological studies on the percutaneous uptake of [14C] ethylenediamine in the rat.
Anuszkiewicz, CM; Chu, SC; Garman, RH; McKelvey, JA; Tallant, MJ; Yang, RS, 1987
)
0.5
" The studies demonstrated a direct relationship between dosage levels of EDDI and serum iodine levels."( Efficacy of ethylenediamine dihydriodide as an agent to prevent experimentally induced bovine foot rot.
Berg, JN; Davis, LE; Krause, GF; Maas, JP; Paterson, JA, 1984
)
0.65
"3HCl) were studied with regard to route of administration and dosage effects."( Pharmacokinetics and material balance studies of diethylenetriamine trihydrochloride in the Fischer 344 rat following oral, endotracheal or intravenous dosing.
Leung, HW; Tyler, TR,
)
0.13
" The following results were obtained: 1) Pharmacokinetic parameters of plasma theophylline after an intravenous bolus injection were close to those after the dosing of aminophylline in dogs by a crossover method."( Pharmacokinetic study of theophylline in dogs after intravenous administration with and without ethylenediamine.
Kawai, H; Kojima, J; Kokubun, S; Matsumoto, T; Onodera, K, 2000
)
0.53
" The potential salt form would ideally decrease the rate of (SBE)7M-beta-CD release from osmotic pump formulations and result in an increase in the rate and extent of drug release in osmotic pump tablet and pellet dosage forms."( Evaluation of various properties of alternative salt forms of sulfobutylether-beta-cyclodextrin, (SBE)7M-beta-CD.
Haslam, JL; Sotthivirat, S; Stella, VJ, 2007
)
0.34
" Interestingly, Ba(2+) did shift the K(+) dose-response curve."( Divalent cation interactions with Na,K-ATPase cytoplasmic cation sites: implications for the para-nitrophenyl phosphatase reaction mechanism.
Arnett, KL; Gatto, C; Milanick, MA, 2007
)
0.34
"This study aimed at investigating the effects of trace metals on methane production from food waste and examining the feasibility of reducing metals dosage by ethylenediamine-N,N'-disuccinic acid (EDDS) via improving metals bioavailability."( Enhanced anaerobic digestion of food waste by trace metal elements supplementation and reduced metals dosage by green chelating agent [S, S]-EDDS via improving metals bioavailability.
Li, A; Zhang, L; Zhang, W, 2015
)
0.61
", 50% reduction in the dosage of EDTA was made possible."( Combined application of EDDS and EDTA for removal of potentially toxic elements under multiple soil washing schemes.
Baek, K; Beiyuan, J; Bolan, NS; Li, XD; Ok, YS; Rinklebe, J; Tsang, DCW; Valix, M; Zhang, W, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
GABA agonistA drug that binds to and activates gamma-aminobutyric acid receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
alkane-alpha,omega-diamineA primary diamine that is ethane or a higher alkane in which a hydrogen of each of the terminal methyl groups has been replaced by an amino group. H2NCH2(CH2)nCH2NH2, where n = 0, 1, 2, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency1.97050.000714.592883.7951AID1259369
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency6.99170.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.41190.000229.305416,493.5996AID588514; AID743069; AID743075; AID743077; AID743078; AID743079
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency0.08910.01789.637444.6684AID588834
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency53.08040.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)IC50 (µMol)15,500.00000.00050.471610.0000AID72823
Protein farnesyltransferase subunit betaHomo sapiens (human)IC50 (µMol)15,500.00000.00050.21772.5000AID72823
Glutaminyl-peptide cyclotransferaseMus musculus (house mouse)Ki22,000.00006.40006.40006.4000AID1796111
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
transforming growth factor beta receptor signaling pathwayProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of Rac protein signal transductionProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of tubulin deacetylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of deacetylase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
lipid metabolic processProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
Rab geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
receptor tyrosine kinase bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
alpha-tubulin bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
molecular adaptor activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
zinc ion bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytosolProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
plasma membraneProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytoplasmProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytosolProtein farnesyltransferase subunit betaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID72823Inhibition of [3H]farnesyl pyrophosphate binding to human farnesyltransferase2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
A novel metal-chelating inhibitor of protein farnesyltransferase.
AID450458Antibacterial activity against Bacillus subtilis after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID448534Cytotoxicity against Mycobacterium bovis Bacillus Calmette-Guerin infected mouse J774 macrophage assessed as cell viability at 100 ug/mL after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Antitubercular activity of alpha,omega-diaminoalkanes, H2N(CH2)nNH2.
AID448380Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as minimum inhibitory concentration after 24 hrs by micro plate Alamar blue assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Antitubercular activity of alpha,omega-diaminoalkanes, H2N(CH2)nNH2.
AID1651254Induction of DPPH reduction by H2S2 generated from parent compound by UV spectrometry2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Diacyl disulfides as the precursors for hydrogen persulfide (H
AID448533Cytotoxicity against Mycobacterium bovis Bacillus Calmette-Guerin infected mouse J774 macrophage assessed as cell viability at 10 ug/mL after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Antitubercular activity of alpha,omega-diaminoalkanes, H2N(CH2)nNH2.
AID1327557Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 0.05 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1327562Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 2 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID448381Cytotoxicity against mouse J774 macrophage assessed as cell viability at 1 ug/mL after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Antitubercular activity of alpha,omega-diaminoalkanes, H2N(CH2)nNH2.
AID448530Cytotoxicity against mouse J774 macrophage assessed as cell viability at 10 ug/mL after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Antitubercular activity of alpha,omega-diaminoalkanes, H2N(CH2)nNH2.
AID1327556Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 0.02 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID448531Cytotoxicity against mouse J774 macrophage assessed as cell viability at 100 ug/mL after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Antitubercular activity of alpha,omega-diaminoalkanes, H2N(CH2)nNH2.
AID450460Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID1327559Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 0.1 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID450459Antibacterial activity against Serratia marcescens after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID1327545Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 200 uM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1327560Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 0.5 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1327544Antioxidant activity assessed as inhibition of AAPH-induced peroxyl radical generation measured as trolox equivalent at 10 uM preincubated for 30 mins followed by AAPH addition measured evey 60 secs for 60 cycles by ORAC-FL assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1327543Reactive carbonyl species trapping activity of compound assessed as MDA adduct formation at 10 mM preincubated for 24 hrs with MDA measured after 1 hr by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID74488Inhibitory activity against murine gelatinase B at 5 mM was determined2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Design and synthesis of novel inhibitors of gelatinase B.
AID448532Cytotoxicity against Mycobacterium bovis Bacillus Calmette-Guerin infected mouse J774 macrophage assessed as cell viability at 1 ug/mL after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Antitubercular activity of alpha,omega-diaminoalkanes, H2N(CH2)nNH2.
AID1651238Drug metabolism in THF assessed as release of hydrogen disulphide at 5 mM in presence of S-acetylsulfanylethanethioate by DSP-3 probe based fluorescence assay2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Diacyl disulfides as the precursors for hydrogen persulfide (H
AID1327561Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 1 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1327558Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 0.08 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID450461Antibacterial activity against Escherichia coli after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID450457Antibacterial activity against Staphylococcus aureus after 24 hrs by twofold serial dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Interaction of drug based binuclear mixed-ligand complexes with DNA.
AID1327542Reactive carbonyl species trapping activity of compound assessed as MGO adduct formation at 10 mM preincubated for 24 hrs with MGO measured after 15 mins by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1796111QC Inhibition Testing from Article 10.1021/bi051142e: \\Isolation, catalytic properties, and competitive inhibitors of the zinc-dependent murine glutaminyl cyclase.\\2005Biochemistry, Oct-11, Volume: 44, Issue:40
Isolation, catalytic properties, and competitive inhibitors of the zinc-dependent murine glutaminyl cyclase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (840)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990234 (27.86)18.7374
1990's81 (9.64)18.2507
2000's180 (21.43)29.6817
2010's306 (36.43)24.3611
2020's39 (4.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.92 (24.57)
Research Supply Index6.78 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index133.09 (26.88)
Search Engine Supply Index2.13 (0.95)

This Compound (70.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (0.69%)5.53%
Reviews7 (0.80%)6.00%
Case Studies47 (5.40%)4.05%
Observational0 (0.00%)0.25%
Other810 (93.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]